May 22, 2024 – Talk Bio

FDA Grants Approval for First Interchangeable Biosimilars to Regeneron’s Eylea

11 months ago talkbio0Tagged Approved, Biosimilars, blockbuster, Diabetic Retinopathy, interchangeable, Macular degeneration, Regeneron, Retinal Vein Occlusion, United States Food and Drug Administration

FDA, biosimilars, interchangeable, Regeneron, Eylea, approval, blockbuster, drug, treatment, eye diseases, macular degeneration, diabetic retinopathy, retinal vein occlusion

Sen. Wyden Scrutinizes Pfizer’s Tax Rate Amidst Ongoing Investigation

11 months ago talkbio0Tagged Avoidance, Corporate, Drug Industry, Evaluation, financial transparency, Pfizer, Rating (action), Taxation, Wyden

Sen. Wyden, Pfizer, tax rate, investigation, corporate taxation, tax avoidance, pharmaceutical industry, financial transparency

Biogen Expands Immunology Portfolio with $1.15 Billion Acquisition of HI-Bio

11 months ago talkbio0Tagged Acquisition (action), Biogen, Drug Development, expansion, HI-Bio, Immunology

Biogen, HI-Bio, acquisition, immunology, $1.15 billion, expansion, therapeutics, drug development

Otsuka Discontinues Alzheimer’s Agitation Drug Development Following Second Unsuccessful Trial

11 months ago talkbio0Tagged Agitation, Alzheimer 's disease, Clinical Trials, Discontinuation (procedure), Drug Development, Failed, Otsuka, trials

Otsuka, Alzheimer’s disease, agitation, drug development, clinical trials, failed trials, discontinuation

Tremfya Emerges as a Promising Successor to Stelara in J&J’s Pipeline with Robust Clinical Data

11 months ago talkbio0Tagged Biological Factors, Clinical Trials, head-to-head data, J&J, Psoriasis, Stelara, successor, Tremfya

J&J, Tremfya, Stelara, successor, head-to-head data, clinical trials, psoriasis treatment, biologics.

Biopharma Downsizing Trends 2024: Major Companies Adjusting Workforce

11 months ago talkbio0Tagged Biopharma, Industry, Takeda, trends qualifier

Biopharma, layoffs, downsizing, workforce reduction, Evotec, Lyra Therapeutics, Takeda Pharmaceuticals, industry trends, 2024

Pheon Secures $120 Million in Series B Funding to Revolutionize Treatment for Challenging Cancers with Advanced Antibody-Drug Conjugates

11 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Biotechnology, Cancer Therapeutic Procedure, hard-to-treat cancers, healthcare innovation, Pheon, Series B

Pheon, Series B funding, $120 million, hard-to-treat cancers, antibody-drug conjugates (ADCs), cancer treatment, biotechnology, healthcare innovation.